Linganisha mbinu

	Kipimo cha Hemolysis	Assay ya utando wa chorioallantoic (CAM)	Kipimo cha MTT/MTS
Nyanja	Biomateriali	Biomateriali	Biomateriali
Familia	Process / pipeline	Process / pipeline	Process / pipeline
Mwaka wa asili	1950	1974	1983
Mwanzilishi	Clinical hematology traditions	Judah Folkman	Tatsuro Mosmann
Aina	Hemolytic compatibility assay	Developmental biology assay	Colorimetric assay
Chanzo asilia	ASTM F756-17 (2017). Standard Practice for Assessment of Hemolytic Properties of Materials. ASTM International.	Folkman, J. (1974). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186.	Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1-2), 55-63.
Majina mbadala	RBC lysis assay, hemolytic compatibility test, hemolytic potential test	chick embryo chorioallantoic membrane, angiogenesis assay, CAM angiogenesis model	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, tetrazolium assay, mitochondrial activity assay
Zinazohusiana	4	4	4
Muhtasari	The hemolysis assay is a standard method for evaluating the blood compatibility of biomaterials by quantifying the extent to which a material or substance damages red blood cells (RBCs) and causes hemoglobin release. Codified in standards including ASTM F756 and ISO 10993-4, the hemolysis assay is essential for regulatory approval of blood-contacting devices such as stents, catheters, artificial heart valves, and hemodialysis membranes. The assay provides a simple, quantitative measure of hemolytic potential that correlates with clinical safety.	The chorioallantoic membrane (CAM) assay is a well-established in vivo model for studying angiogenesis (new blood vessel formation) and evaluating the pro- or anti-angiogenic properties of biomaterials, drugs, and bioactive molecules. Developed by Judah Folkman in the 1970s, the assay uses the highly vascularized CAM of developing chick embryos as a platform for implanting test materials and observing vascular response. The CAM provides a transparent, immunologically naive microenvironment with rapid and reproducible neovascularization, making it ideal for screening angiogenic potential and assessing biomaterial biocompatibility.	The MTT assay, introduced by Tatsuro Mosmann in 1983, is a colorimetric method for quantifying cell viability and proliferation by measuring mitochondrial metabolic activity. The method detects the conversion of the water-soluble tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by active mitochondria, producing an insoluble purple formazan precipitate proportional to the number of viable cells. The related MTS assay, which does not require solubilization, offers improved kinetics and is now widely adopted in both academic research and pharmaceutical development.